Belantamab mafodotin vs Zevorcabtagene autoleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Belantamab mafodotin

Marketed by GlaxoSmithKline

Approved in Multiple Myelomaantibody-drug conjugate (anti-BCMA, MMAF payload)
Partial signal

NCT04246047 · Phase 3 · active, not recruiting

Patients were randomized (243 vs 251) against an active comparator and the primary endpoint of progression-free survival, assessed by an independent review committee, was met with a large separation (hazard ratio 0.41, p<0.00001). The study was open-label with no masking of participants or investigators, which keeps it below the highest grade.

Next expected readout: February 2027 · NCT05055063 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to approximately 41 months): Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5) (met)

Result source: NCT04246047

Zevorcabtagene autoleucel

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

Phase 1/2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03975907 · Phase 1/2 · status unknown

This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).

Reported efficacy

Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)

Result source: NCT03975907

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBelantamab mafodotinZevorcabtagene autoleucel
PFS, median36.6 vs 13.4vs Daratumumabn 243NCT04246047
13 other results
  • 11.2 vs 7 n 218 · Phase 3 · primary NCT04162210
  • 3.2 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 3.9 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 2.2 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 2.8 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 3.6 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 2.5 mg/kg Q3W · n 29 · Phase 2 · secondary NCT05064358
  • 2.8 2.5 mg/kg Q6W · n 30 · Phase 2 · secondary NCT05064358
  • 2.5 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · secondary NCT03848845
  • 2.1 1.9 mg/kg Q3W · n 30 · Phase 2 · secondary NCT05064358
  • 2.7 1.9 mg/kg Q6W · n 34 · Phase 2 · secondary NCT05064358
  • 2.8 1.9 mg/kg Q6W · n 11 · Phase 2 · secondary NCT05064358
—Not reported
OS, median24 vs 22.9vs Pomalidomide Plus Dexamethasonen 218NCT04162210
7 other results
  • 14 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 15.3 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 24.5 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 20.9 2.5 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 13.5 2.5 mg/kg Q6W · n 25 · Phase 2 · secondary NCT05064358
  • 15 1.9 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 14.5 1.9 mg/kg Q6W · n 21 · Phase 2 · secondary NCT05064358
—Not reported
ORR41% vs 36%vs Pomalidomide Plus Dexamethasonen 218NCT04162210
35 other results
  • 34% 3.4 mg/kg · n 99 · Phase 2 · primary NCT03525678
  • 30% 3.4 mg/kg · n 66 · Phase 2 · primary NCT03525678
  • 31% 2.5 mg/kg · n 97 · Phase 2 · primary NCT03525678
  • 48% 3.4 mg/kg · n 25 · Phase 2 · primary NCT03525678
  • 30% 2.5 mg/kg · n 64 · Phase 2 · primary NCT03525678
  • 50% 3.4 mg/kg SPLIT · n 12 · Phase 1/2 · primary NCT03544281
  • 69% 3.4 mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 92% 2.5 mg/kg Step-Down STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 2.5 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 62% 2.5 mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 78% 2.5 mg/kg SINGLE · n 18 · Phase 1/2 · primary NCT03544281
  • 43% 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · primary NCT03848845
  • 58% 1.9mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 50% 1.9 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 83% 1.9 mg/kg SINGLE · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 1.9mg/kg SINGLE · n 4 · Phase 1/2 · primary NCT03544281
  • 32% 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 52% 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 26% 3.4 mg/kg · n 66 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 64 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 28% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 43% 3.4 mg/kg + 200 mg · n 7 · Phase 1/2 · secondary NCT03848845
  • 67% 2.5 mg/kg + 200 mg · n 6 · Phase 1/2 · secondary NCT03848845
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
  • 25% 3.4 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 100% 2.5 mg/kg + Bor/Dex · n 3 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 16.7% n 6 · Phase 1 · secondary NCT04177823
—Not reported
VGPR or better25%b2.5 mg/kg Q3W · n 40NCT05064358
4 other results
  • 8% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 15% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
—Not reported
MRD negativity—Trial running · NCT06679101—Not reported

PFS, median

Belantamab mafodotin
36.6 vs 13.4vs Daratumumabn 243NCT04246047
13 other results
  • 11.2 vs 7 n 218 · Phase 3 · primary NCT04162210
  • 3.2 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 3.9 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 2.2 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 2.8 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 3.6 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 2.5 mg/kg Q3W · n 29 · Phase 2 · secondary NCT05064358
  • 2.8 2.5 mg/kg Q6W · n 30 · Phase 2 · secondary NCT05064358
  • 2.5 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · secondary NCT03848845
  • 2.1 1.9 mg/kg Q3W · n 30 · Phase 2 · secondary NCT05064358
  • 2.7 1.9 mg/kg Q6W · n 34 · Phase 2 · secondary NCT05064358
  • 2.8 1.9 mg/kg Q6W · n 11 · Phase 2 · secondary NCT05064358
Zevorcabtagene autoleucel
—Not reported

OS, median

Belantamab mafodotin
24 vs 22.9vs Pomalidomide Plus Dexamethasonen 218NCT04162210
7 other results
  • 14 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 15.3 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 24.5 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 20.9 2.5 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 13.5 2.5 mg/kg Q6W · n 25 · Phase 2 · secondary NCT05064358
  • 15 1.9 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 14.5 1.9 mg/kg Q6W · n 21 · Phase 2 · secondary NCT05064358
Zevorcabtagene autoleucel
—Not reported

ORR

Belantamab mafodotin
41% vs 36%vs Pomalidomide Plus Dexamethasonen 218NCT04162210
35 other results
  • 34% 3.4 mg/kg · n 99 · Phase 2 · primary NCT03525678
  • 30% 3.4 mg/kg · n 66 · Phase 2 · primary NCT03525678
  • 31% 2.5 mg/kg · n 97 · Phase 2 · primary NCT03525678
  • 48% 3.4 mg/kg · n 25 · Phase 2 · primary NCT03525678
  • 30% 2.5 mg/kg · n 64 · Phase 2 · primary NCT03525678
  • 50% 3.4 mg/kg SPLIT · n 12 · Phase 1/2 · primary NCT03544281
  • 69% 3.4 mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 92% 2.5 mg/kg Step-Down STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 2.5 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 62% 2.5 mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 78% 2.5 mg/kg SINGLE · n 18 · Phase 1/2 · primary NCT03544281
  • 43% 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · primary NCT03848845
  • 58% 1.9mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 50% 1.9 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 83% 1.9 mg/kg SINGLE · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 1.9mg/kg SINGLE · n 4 · Phase 1/2 · primary NCT03544281
  • 32% 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 52% 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 26% 3.4 mg/kg · n 66 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 64 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 28% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 43% 3.4 mg/kg + 200 mg · n 7 · Phase 1/2 · secondary NCT03848845
  • 67% 2.5 mg/kg + 200 mg · n 6 · Phase 1/2 · secondary NCT03848845
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
  • 25% 3.4 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 100% 2.5 mg/kg + Bor/Dex · n 3 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 16.7% n 6 · Phase 1 · secondary NCT04177823
Zevorcabtagene autoleucel
—Not reported

VGPR or better

Belantamab mafodotin
25%b2.5 mg/kg Q3W · n 40NCT05064358
4 other results
  • 8% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 15% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
Zevorcabtagene autoleucel
—Not reported

MRD negativity

Belantamab mafodotin
—Trial running · NCT06679101
Zevorcabtagene autoleucel
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Zevorcabtagene autoleucel
LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). NCT03975907 · Phase 1/2 · design grade: weak · publication or press release
LUMMICAR STUDY 2 (NCT03915184): objective response rate 100% in evaluable relapsed/refractory multiple myeloma patients. NCT03915184 · Phase 1/2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Belantamab mafodotin: 3 of 4 rows · Zevorcabtagene autoleucel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBelantamab mafodotin
Dropout rate
n/a: no completion milestonea
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
42.2%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
n/a: no completion milestone3.4 mg/kg
NCT03525678 · Phase 2
n/a: no completion milestone3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
n/a: no completion milestone2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
75%2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
80%2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
82.5%1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
77.5%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
58.8%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
50%3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
77.8%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
87.5%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
75%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
42.9%3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
32.1%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
25%3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
0%2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
33.3%
NCT04177823 · Phase 1 · registry result, not featured evidence
16.7%4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
33.3%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
—
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
—3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
—2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
—3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—
NCT04177823 · Phase 1 · registry result, not featured evidence
—4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
Serious AEs
50%a
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
46.5%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
53.5%3.4 mg/kg
NCT03525678 · Phase 2
62.5%3.4 mg/kg
NCT03525678 · Phase 2
100%3.4 mg/kg
NCT03525678 · Phase 2
45.3%2.5 mg/kg
NCT03525678 · Phase 2
100%2.5 mg/kg
NCT03525678 · Phase 2
43.6%2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
53.8%2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
42.5%1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
40%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
23.5%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
56.3%3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
72.2%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
53.8%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
62.5%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
46.2%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
25%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
25%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
33.3%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
71.4%3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
66.7%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
17.9%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
0%3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
50%2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
0%2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
25%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
50%2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
0%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
16.7%
NCT04177823 · Phase 1 · registry result, not featured evidence
50%4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
33.3%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
48.6%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
thrombocytopenia 69%
vision blurred 66.1%
dry eye 50.8%
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
vision blurred 48.4%
dry eye 37.8%
foreign body sensation in eyes 36.9%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
3.4 mg/kg
keratopathy 74.7%
thrombocytopenia 44.4%
anaemia 36.4%
NCT03525678 · Phase 2
3.4 mg/kg
keratopathy 95.8%
fatigue 50%
anaemia 33.3%
NCT03525678 · Phase 2
3.4 mg/kg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03525678 · Phase 2
2.5 mg/kg
keratopathy 70.5%
anaemia 26.3%
nausea 25.3%
NCT03525678 · Phase 2
2.5 mg/kg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03525678 · Phase 2
2.5 mg/kg Q3W
vision blurred 41%
dry eye 38.5%
eye irritation 28.2%
NCT05064358 · Phase 2 · registry result, not featured evidence
2.5 mg/kg Q6W
vision blurred 46.2%
thrombocytopenia 33.3%
anaemia 30.8%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q3W
thrombocytopenia 42.5%
anaemia 30%
dry eye 30%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q6W
anaemia 37.5%
dry eye 30%
eye irritation 27.5%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q6W
vision blurred 52.9%
dry eye 47.1%
eye irritation 29.4%
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
3.4 mg/kg SINGLE
keratopathy 93.8%
thrombocytopenia 56.3%
neuropathy peripheral 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg SPLIT
keratopathy 83.3%
thrombocytopenia 75%
fatigue 41.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SINGLE
keratopathy 83.3%
vision blurred 66.7%
platelet count decreased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SPLIT
keratopathy 76.9%
thrombocytopenia 69.2%
vision blurred 38.5%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg STRETCH
keratopathy 100%
platelet count decreased 58.3%
gamma-glutamyltransferase increased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg Step-Down STRETCH
keratopathy 100%
platelet count decreased 58.3%
diarrhoea 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SINGLE
keratopathy 68.8%
fatigue 43.8%
thrombocytopenia 43.8%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SPLIT
keratopathy 92.3%
vision blurred 53.8%
diarrhoea 46.2%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg Step-Down STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg SINGLE
keratopathy 91.7%
platelet count decreased 75%
constipation 66.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg STRETCH
keratopathy 75%
diarrhoea 50%
platelet count decreased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg SINGLE
diarrhoea 75%
keratopathy 75%
abdominal pain 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg STRETCH
keratopathy 75%
diarrhoea 41.7%
insomnia 41.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg + 200 mg
keratopathy 85.7%
pyrexia 57.1%
anaemia 42.9%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
keratopathy 100%
anaemia 66.7%
blepharitis 50%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
keratopathy 71.4%
pyrexia 35.7%
vision blurred 35.7%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg
diarrhoea 50%
enterocolitis 50%
headache 50%
NCT03828292 · Phase 1 · registry result, not featured evidence
2.5 mg/kg
platelet count decreased 100%
alanine aminotransferase increased 50%
aspartate aminotransferase increased 50%
NCT03828292 · Phase 1 · registry result, not featured evidence
2.5 mg/kg + Bor/Dex
thrombocytopenia 100%
diarrhoea 66.7%
insomnia 66.7%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
constipation 50%
neutrophil count decreased 50%
oedema peripheral 50%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Bor/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
blood lactate dehydrogenase increased 66.7%
hyponatraemia 66.7%
lymphocyte count decreased 66.7%
NCT04177823 · Phase 1 · registry result, not featured evidence
4.60 mg/kg
thrombocytopenia 83.3%
aspartate aminotransferase increased 66.7%
fatigue 66.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 100%
aspartate aminotransferase increased 66.7%
chills 66.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 51.4%
cough 40%
aspartate aminotransferase increased 37.1%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 33.3%
anaemia 16.7%
blood creatine phosphokinase increased 16.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
2.50 mg/kg
anaemia 37.5%
fatigue 37.5%
nausea 37.5%
NCT02064387 · Phase 1 · registry result, not featured evidence
1.92 mg/kg
nausea 75%
vision blurred 75%
chills 50%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.96 mg/kg
anaemia 66.7%
fatigue 66.7%
chills 33.3%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.48 mg/kg
arthralgia 50%
back pain 25%
decreased appetite 25%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.24 mg/kg
fatigue 50%
nausea 50%
anaemia 25%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.12 mg/kg
cough 50%
hypercalcaemia 50%
nausea 50%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.06 mg/kg
anaemia 100%
diarrhoea 100%
hyperuricaemia 100%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.03 mg/kg
fatigue 100%
neutropenia 100%
osteonecrosis of jaw 100%
NCT02064387 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 55 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Belantamab mafodotin

PFS 36.6 vs 13.4 Daratumumab months
time to event · months
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
11.2 vs 7 Pomalidomide Plus Dexamethasone months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Overall Survival 24 vs 22.9 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
ORR 41% (n=218) vs 36% (n=107) Pomalidomide Plus Dexamethasone
responder rate · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Clinical Benefit 47% (n=218) vs 47% (n=107) Pomalidomide Plus Dexamethasone
responder rate · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Duration of Response 25.3 vs 9.9 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Time to Response 2.1 vs 1.53 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Time to Progression 11.3 vs 8.6 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
MRD Negativity 10.1% (n=218) vs 0.9% (n=107) Pomalidomide Plus Dexamethasone
event count · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 · converted to % from 22 Participants as posted
ORR 34% (n=99)3.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT03525678 · Phase 2
show 34 more results
48% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
30% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
32% (n=99)3.4 mg/kg
NCT03525678 · Phase 2
52% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
26% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
50% (n=12)3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69% (n=16)3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
43% (n=7)3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
25% (n=4)3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
31% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
30% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=40)2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
28% (n=40)2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
69% (n=13)2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69% (n=16)2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
92% (n=12)2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
75% (n=12)2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
62% (n=13)2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
78% (n=18)2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
43% (n=28)2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
67% (n=6)2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
100% (n=3)2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
25% (n=40)1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
25% (n=40)1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
18% (n=17)1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
58% (n=12)1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
75% (n=4)1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=12)1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
83% (n=12)1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
16.7% (n=6)
NCT04177823 · Phase 1 · registry result, not featured evidence
Clinical Benefit 38% (n=99)3.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT03525678 · Phase 2
show 14 more results
60% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
35% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
40% (n=99)3.4 mg/kg
NCT03525678 · Phase 2
56% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
38% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
75% (n=4)3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
35% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
34% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
36% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
34% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
43% (n=28)2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
100% (n=3)2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
Duration of Response 12.6 months3.4 mg/kg
time to event · months
No placebo or comparator arm
NCT03525678 · Phase 2
show 15 more results
5.3 months3.4 mg/kg
NCT03525678 · Phase 2
15.9 months3.4 mg/kg
NCT03525678 · Phase 2
6.2 months3.4 mg/kg
NCT03525678 · Phase 2
9 months3.4 mg/kg
NCT03525678 · Phase 2
15.9 months3.4 mg/kg
NCT03525678 · Phase 2
12.4 months2.5 mg/kg
NCT03525678 · Phase 2
6.9 months2.5 mg/kg
NCT03525678 · Phase 2
12.5 months2.5 mg/kg
NCT03525678 · Phase 2
11 months2.5 mg/kg
NCT03525678 · Phase 2
15.9 months2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
6.2 months2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
7.6 months2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
22.1 months1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
7.8 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
15.9 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
Time to Response 1.5 months3.4 mg/kg
time to event · months
No placebo or comparator arm
NCT03525678 · Phase 2
show 15 more results
0.9 months3.4 mg/kg
NCT03525678 · Phase 2
1.5 months3.4 mg/kg
NCT03525678 · Phase 2
1.4 months3.4 mg/kg
NCT03525678 · Phase 2
0.9 months3.4 mg/kg
NCT03525678 · Phase 2
1.4 months3.4 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1.4 months2.5 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
0.8 months2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
0.7 months2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
0.7 months2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
1.1 months1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
0.8 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
1.5 months1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination

+ 311 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Belantamab mafodotin's landscape · Zevorcabtagene autoleucel's landscape